Molecular Partners (NASDAQ:MOLN - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.14), Zacks reports.
Molecular Partners Stock Performance
Molecular Partners stock traded up $0.55 during midday trading on Monday, reaching $4.22. 28,858 shares of the stock were exchanged, compared to its average volume of 6,418. The company's fifty day moving average is $3.68 and its 200-day moving average is $4.00. The firm has a market cap of $170.40 million, a PE ratio of -2.20 and a beta of 1.10. Molecular Partners has a 52 week low of $3.36 and a 52 week high of $7.60.
About Molecular Partners
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access